PMN ENHANCEMENT OF ENDOTHELIAL RESPONSE TO CANDIDA
Project Number1R29AI040636-01
Contact PI/Project LeaderFILLER, SCOTT G
Awardee OrganizationLUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
Description
Abstract Text
DESCRIPTION (Adapted from the applicant's abstract): The incidence of
bloodstream infections caused by Candida species has increased dramatically,
so that these organisms now account for 10% of all bloodstream isolates.
During the process of hematogenous dissemination, it is likely that
blood-borne organisms must adhere to and penetrate the endothelial lining of
the vasculature to invade the tissue parenchyma. Thus, a potential method
to prevent or treat hematogenously disseminated candidal infections is to
augment the combined response of neutrophils and endothelial cells against
this organism while it is within the intravascular compartment. We have
shown that adding neutrophils to Candida-infected endothelium prevents
endothelial cell injury in vitro. Also, we have found that Candida albicans
by itself can stimulate endothelial cells to express leukocyte adhesion
molecules and proinflammatory cytokines. The expression of these factors is
greatly increased when neutrophils are added to endothelium infected with C.
albicans. Together, these results suggest that there is a two-way exchange
of signals between endothelial cells and neutrophils during their response
to intravascular infection.
The experiments outlined in this proposal are designed to elucidate the
mechanisms that mediate this neutrophil amplification of the endothelial
cell proinflammatory response to C. albicans. The influence of the
microbial target (C. albicans) on the neutrophil enhancement of the
endothelial cell response will be evaluated first. Based on these results,
the immunomodulatory substances that mediate this neutrophil amplification
will be identified. The expression of the leukocyte adhesion molecules,
E-selectin and VCAM-1, will be used as a marker of endothelial cell
activation in these experiments. Next, the activities of the
immunomodulatory substances identified by the above experiments will be
inhibited to determine if theses substances also influence the ability of
neutrophils to kill C. albicans and protect endothelial cells from candidal
injury. Finally, the results of these in vitro experiments will be
evaluated in vivo. Both immunocompetent and neutropenic mice will be
infected with C. albicans and immunohistochemistry will be used to detect
the local expression of leukocyte adhesion molecules and cytokines at sites
of candidal infection. Investigating the interactions between endothelial
cells, neutrophils and C. albicans will enable us to determine the mechanism
by which endothelial cells are activated in response to infection. The
long-range goal of these studies is to devise endothelial cell-based
strategies to enhance the host inflammatory response to blood-borne
microbial pathogens.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
069926962
UEI
LTJVF4QSFCP9
Project Start Date
01-April-1997
Project End Date
31-March-2002
Budget Start Date
01-April-1997
Budget End Date
31-March-1998
Project Funding Information for 1997
Total Funding
$98,730
Direct Costs
$70,000
Indirect Costs
$28,730
Year
Funding IC
FY Total Cost by IC
1997
National Institute of Allergy and Infectious Diseases
$98,730
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R29AI040636-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R29AI040636-01
Patents
No Patents information available for 1R29AI040636-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R29AI040636-01
Clinical Studies
No Clinical Studies information available for 1R29AI040636-01
News and More
Related News Releases
No news release information available for 1R29AI040636-01
History
No Historical information available for 1R29AI040636-01
Similar Projects
No Similar Projects information available for 1R29AI040636-01